In the Brief Report titled “Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma,”1 published online March 25, 2021, a grant from the New York University’s Specialized Program of Research Excellence in Melanoma was omitted from the Funding/Support section. This article has been corrected online.
Reference
- 1.Patrinely JR Jr, Johnson R, Lawless AR, et al. Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma. JAMA Oncol. Published online March 25, 2021. doi: 10.1001/jamaoncol.2021.0051 [DOI] [PMC free article] [PubMed] [Google Scholar]